亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Novel Triazole Bisphosphonate Geranylgeranyl Diphosphate Synthase Inhibitors

詳細技術說明: Dr.Wiemer’s lab has developed a novel class of triazole bisphosphonategeranylgeranyl diphosphate synthase (GGDPS) inhibitors that can be used assingle isomers. These inhibitors are water-soluble and can be readily synthesized.These compounds target an enzyme in isoprenoid biosynthesis that allows cellsto export proteins. Protein export is important in living organisms; however, manydiseases are characterized by cells that overreact to protein synthesis andexport. These novel compounds can inhibit the export of proteins from thediseased cells, resulting in programmed cell death. Therefore, the inhibitorsrepresent a novel therapeutic strategy for the treatment of various diseases,including multiple myeloma and other types of cancers.

*Abstract: Enzymesof the isoprenoid biosynthetic pathway are the target of many drugs, due totheir importance in the export of proteins. One common therapeutic strategyused for the treatment of osteoporosis and other diseases of the bone has beeninhibition of the enzyme farnesyl diphosphate synthase (FDPS). However, inhibitors of the enzymegeranylgeranyl diphosphate synthase (GGDPS) may be a more direct means to thebiological effects desired from FDPS inhibitors. The most potent GGDPSinhibitors have typically been mixtures of isomers. Unfortunately, the precisecomposition of these isomeric mixtures is very difficult to replicate, limitingtheir clinical applicability and favoring an inhibitor that can be used as asingle isomer.

欲了解更多信息，請點擊這裡